Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
ROOT, Switzerland–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including... Read more.
Northern Trust Named Best Private Bank for Family Offices and Succession Planning
CHICAGO–(BUSINESS WIRE)–#wealthmanagement–Northern Trust, a leading provider of wealth management services, has taken top honors in two categories... Read more.
NanoSyrinx appoints Anthony Johnson as Non-Executive Director
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy COVENTRY, United Kingdom–(BUSINESS WIRE)–NanoSyrinx,... Read more.
Merck Receives Positive EU CHMP Opinion for KEYTRUDAยฎ (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Opinion granted based on positive overall survival results from the Phase 3 KEYNOTE‑966 trial RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck... Read more.
National Vision Holdings, Inc. Announces Repurchase of $100 Million of Convertible Notes
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision”) today announced that it has entered into agreements... Read more.
Bowman Acquires Reno-Based Engineering Firm CFA, Inc.
RESTON, Va.–(BUSINESS WIRE)–Bowman Consulting Group Ltd. (the “Company” or “Bowman”) (NASDAQ: BWMN), a national engineering... Read more.
CI Financial Announces Commencement of Substantial Issuer Bid
TORONTO–(BUSINESS WIRE)–$CIX #CIFinancial–CI Financial Corp. (TSX: CIX) (“CI Financial” or the “Corporation”) announced... Read more.
FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting
PHILADELPHIA–(BUSINESS WIRE)–FORE Biotherapeutics today announced an oral presentation highlighting updated Phase 1/2a clinical data for plixorafenib... Read more.
Soho House & Co Inc. Announces Third Quarter 2023 Results
LONDON–(BUSINESS WIRE)–$SHCO–Soho House & Co Inc. (NYSE: SHCO) (“SHCO,” “Company,” “we” or “our”),... Read more.
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that... Read more.